Brachytherapy for restenosis after stenting for coronary artery disease: Its role in the drug-eluting stent era

Current Opinion in Cardiology

Volumn 19, Issue 6, 2004, Pages 601-607

  Kaluza, Grzegorz L ^a   Raizner, Albert E ^a  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

Drug eluting stents; Restenosis; Vascular brachytherapy

Indexed keywords

IRIDIUM 192; PHOSPHORUS 32; STRONTIUM 90; YTTRIUM 90;

APPARATUS; BETA RADIATION; BRACHYTHERAPY; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG ELUTING STENT; FOLLOW UP; GAMMA RADIATION; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HUMAN; OUTCOMES RESEARCH; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RESTENOSIS; REVIEW; THROMBOSIS; TREATMENT FAILURE; VASCULAR BRACHYTHERAPY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BRACHYTHERAPY; CORONARY ARTERIOSCLEROSIS; CORONARY RESTENOSIS; HUMANS; RECURRENCE; STENTS; THROMBOSIS;

EID: 8344260571     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hco.0000142069.39957.03     Document Type: Review

References (59)

1. Nguyen-Ho P, Kaluza GL, Zymek PT, Raizner AE: Intracoronary brachytherapy. Catheter Cardiovasc Interv 2002, 56:281-288.
2. Arjomand H, Turi ZG, McCormick D, Goldberg S: Percutaneous coronary intervention: historical perspectives, current status, and future directions. Am Heart J 2003, 146:787-796. An excellent up-to-date overview of the current status of PCI, including balanced perspective on options for in-stent restenosis.
3. Lowe HC, Oesterle SN, Khachigian LM: Coronary in-stent restenosis: current status and future strategies. J Am Coll Cardiol 2002, 39:183-193.
4. Rankin JM, Spinelli JJ, Carere RG, et al.: Improved clinical outcome after wide-spread use of coronary-artery stenting in Canada. N Engl J Med 1999, 341:1957-1965.
5. Mehran R, Iakovou I, Dangas G, et al.: Gamma radiation for in-stent restenosis: effect of lesion length on angiographic and clinical outcomes. Catheter Cardiovasc Interv 2004, 61:354-359.
6. Popma JJ, Suntharalingam M, Lansky AJ, et al.: Randomized trial of 90Sr/90Y beta-radiation versus placebo control for treatment of in-stent restenosis. Circulation 2002, 106:1090-1096.
7. Waksman R, Raizner AE, Yeung AC, et al.: Use of localised intracoronary beta radiation in treatment of in-stent restenosis: the INHIBIT randomised controlled trial. Lancet 2002, 359:551-557.
8. Leon MB, Teirstein PS, Moses JW, et al.: Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med 2001, 344:250-256.
9. Shirai K, Lansky AJ, Mintz GS, et al.: Feasibility and efficacy of tandem positioning on angiographic and clinical outcomes in the Intimal Hyperplasia Inhibition with Beta In-Stent Trial. Am J Cardiol 2003, 91:1113-1115.
10. Waksman R, Bhargava B, Mintz GS, et al.: Late total occlusion after intracoronary brachytherapy for patients with in-stent restenosis. J Am Coll Cardiol 2000, 36:65-68.
11. Costa MA, Sabate M, van der Giessen WJ, et al.: Late coronary occlusion after intracoronary brachytherapy. Circulation 1999, 100:789-792.
12. Cha DH, Malik IA, Cheneau E, et al.: Use of restenting should be minimized with intracoronary radiation therapy for in-stent restenosis. Catheter Cardiovasc Interv 2003, 59:1-5. An important retrospective study documenting the compromising influence of additional stenting during VBT on clinical outcomes.
13. Cheneau E, Wu Z, Leborgne L, et al.: Additional stenting promotes intimal proliferation and compromises the results of intravascular radiation therapy: an intravascular ultrasound study. Am Heart J 2003, 146:142-145. An important retrospective study elucidating by intravascular ultrasound the negative impact of use of additional stents during VBT.
14. Waksman R, Ajani AE, White RL, et al.: Prolonged antiplatelet therapy to prevent late thrombosis after intracoronary gamma-radiation in patients with in-stent restenosis: Washington Radiation for In-Stent Restenosis Trial Plus 6 Months of Clopidogrel (WRIST PLUS). Circulation 2001, 103:2332-2335.
15. Waksman R, Ajani AE, Cha DH, et al.: WRIST 12 versus WRIST Plus: twelve versus six months of Clopidogrel for prevention of late total occlusion after gamma radiation therapy for in-stent restenosis [abstract]. J Am Coll Cardiol 2002, 39:46A.
16. Albiero R, Nishida T, Adamian M, et al.: Edge restenosis after implantation of high activity (32)P radioactive beta-emitting stents. Circulation 2000, 101:2454-2457.
17. Kim HS, Waksman R, Cottin Y, et al.: Edge stenosis and geographical miss following intracoronary gamma radiation therapy for in-stent restenosis. J Am Coll Cardiol 2001, 37:1026-1030.
18. Sabate M, Costa MA, Kozuma K, et al.: Geographic miss: a cause of treatment failure in radio-oncology applied to intracoronary radiation therapy. Circulation 2000, 101:2467-2471.
19. Cheneau E, Waksman R, Yazdi H, et al.: How to fix the edge effect of catheter-based radiation therapy in stented arteries. Circulation 2002, 106:2271-2277.
20. Sianos G, Wijns W, de Feyter PJ, Serruys PW: Geographical miss during centered intracoronary beta-radiation with 90Yttrium: incidence and implications for recurrence rates after vascular brachytherapy for de novo lesions. Int J Cardiovasc Intervent 2003, 5:181-189. An angiographic study adding to earlier work linking geographic miss, edge effect, and suboptimal outcome of VBT.
21. Condado JA, Waksman R, Saucedo JF, et al.: Five-year clinical and angiographic follow-up after intracoronary iridium-192 radiation therapy. Cardiovasc Radiat Med 2002, 3:74-81.
22. Grise MA, Massullo V, Jani S, et al.: Five-year clinical follow-up after intracoronary radiation: results of a randomized clinical trial. Circulation 2002, 105:2737-2740.
23. Waksman R, Ajani AE, White RL, et al.: Two-year follow-up after beta and gamma intracoronary radiation therapy for patients with diffuse in-stent restenosis. Am J Cardiol 2001, 88:425-428.
24. Waksman R, Ajani AE, White RL, et al.: Five-year follow-up after intracoronary gamma radiation therapy for in-stent restenosis. Circulation 2004, 109:340-344. A seminal study demonstrating durability of antirestenotic effects of gamma VBT out to 5 years. In 130 patients randomly assigned to VBT and placebo, despite some gradual loss of efficacy over time, patients subjected to VBT had a significantly lower frequency of adverse events, remarkably maintained from 6 months through 2 years out to 5 years.
25. Prpic R, Teirstein PS, Reilly JP, et al.: Long-term outcome of patients treated with repeat percutaneous coronary intervention after failure of gamma-brachytherapy for the treatment of in-stent restenosis. Circulation 2002, 106:2340-2345.
26. Ajani AE, Waksman R, Cheneau E, et al.: The outcome of percutaneous coronary intervention in patients with in-stent restenosis who failed intracoronary radiation therapy. J Am Coll Cardiol 2003, 41:551-556. The largest study to date investigating further clinical course and outcomes of VBT failures. It demonstrated that recurrent restenosis after VBT failure is usually focal and easily treatable with conventional balloon angioplasty.
27. Saia F, Sianos G, Hoye A, et al.: Long-term outcome of percutaneous coronary interventions following failed beta-brachytherapy. J Invasive Cardiol 2004, 16:60-64. A small single-center retrospective study examining the further fate of patients who have failed to respond to beta VBT.
28. Limpijankit T, Mehran R, Mintz GS, et al.: Long-term follow-up of patients after gamma intracoronary brachytherapy failure (from GAMMA-I, GAMMA-II, and SCRIPPS-III). Am J Cardiol 2003, 92:315-318. A retrospective analysis of three pooled trials investigated gamma VBT failures and suggested that coronary bypass grafting provided more durable effect than repeat angioplasty after recurrence following failed gamma VBT.
29. Waksman R, Cheneau E, Ajani AE, et al.: Intracoronary radiation therapy improves the clinical and angiographic outcomes of diffuse in-stent restenotic lesions: results of the Washington Radiation for In-Stent Restenosis Trial for Long Lesions (Long WRIST) Studies. Circulation 2003, 107:1744-1749. A designated study focusing on exceptionally long in-stent restenotic lesions showed that even with average lesion length of 36 to 80 mm, gamma radiotherapy was still superior to conventional treatment of in-stent restenosis.
30. Coen V, Serruys P, Sauerwein W, et al,: RENO, a European postmarket surveillance registry, confirms effectiveness of coronary brachytherapy in routine clinical practice. Int J Radiat Oncol Biol Phys 2003, 55:1019-1026. A slightly more detailed secondary analysis of the largest real-world registry of VBT (Urban et al., Heart J 2003, 24:604-612) in clinical practice published to date, including angiographic data.
31. Naber CK, Baumgart D, Bonan R, et al.: Intracoronary brachytherapy, a promising treatment option for diabetic patients: results from a European multicenter registry (RENO). Catheter Cardiovasc Interv 2004, 61:173-178. A substudy from a European registry showing efficacy in VBT in diabetic patients with in-stent restenosis, who traditionally have presented a high risk for recurrence with conventional treatment.
32. Urban P, Serruys P, Baumgart D, et al.: A multicentre European registry of intraluminal coronary beta brachytherapy. Eur Heart J 2003, 24:604-612. The largest real-world registry of VBT in clinical practice published to date. In 1098 patients treated with beta VBT (Novoste system) in 46 European centers, an overall low-frequency of clinical cardiac events was shown (18.7%). This study demonstrated convincingly that the benefits of VBT seen in clinical trials can be reproduced in everyday clinical practice.
33. Young JJ, Marcus DP, Abbottsmith CW, et al.: Durable clinical benefit following Sr90 Beta irradiation therapy for in-stent restenosis in high-volume community practice. J Invasive Cardiol 2003, 15(suppl A):9A-13A. Despite a single-center registry character, this study featured a significant number of patients and demonstrated an impressively high efficacy of beta VBT in daily clinical practice in the United States.
34. Shirai K, Lansky AJ, Mintz GS, et al.: Comparison of the angiographic outcomes after beta versus gamma vascular brachytherapy for treatment of instent restenosis. Am J Cardiol 2003, 92:1409-1413. An elegant retrospective study of the contemporaneous outcomes of gamma and beta VBT in matched patient subsets.
35. Ajani AE, Waksman R, Cheneau E, et al.: Impact of intracoronary radiation on in-stent restenosis involving ostial lesions. Catheter Cardiovasc Interv 2003, 58:175-180. Examined retrospectively the subset of ostial lesions treated with VBT and demonstrated its superior efficacy in comparison to placebo in this challenging patient subset with high risk for restenosis recurrence.
36. Costantini CO, Lansky AJ, Mintz GS, et al.: Intravascular brachytherapy for native coronary ostial in-stent restenotic lesions. J Am Coll Cardiol 2003, 41:1725-1731. Examined retrospectively the subset of ostial lesions treated with VBT and demonstrated its superior efficacy in comparison to placebo in this challenging patient subset with high risk for restenosis recurrence.
37. Baumgart D, Bonan R, Naber C, et al.: Successful reduction of in-stent restenosis in long lesions using beta-radiation: subanalysis from the RENO registry. Int J Radiat Oncol Biol Phys 2004, 58:817-827. A substudy of the RENO registry (Urban et al., Eur Heart J 2003, 24:604-612) showing efficacy of beta VBT in long lesions maintained in routine clinical practice.
38. Heuser R, Laskey W, Lansky A, et al.: Beta radiation in lesions > 15 mm: a START subgroup. J Invasive Cardiol 2003, 15:641-643.
39. Ajani AE, Waksman R, Cheneau E, et al.: Comparison of intracoronary gamma radiation for in-stent restenosis in saphenous vein grafts versus native coronary arteries. Am J Cardiol 2003, 91:22-26. This study examined retrospectively the subset of saphenous vein graft treated with gamma VBT and demonstrated its superior efficacy in comparison to placebo in this challenging patient subset with high risk for restenosis recurrence.
40. Schiele TM, Regar E, Silber S, et al.: Clinical and angiographie acute and follow up results of intracoronary beta brachytherapy in saphenous vein bypass grafts: a subgroup analysis of the multicentre European Registry of Intraluminal Coronary Beta Brachytherapy (RENO). Heart 2003, 89:640-644. A substudy of the RENO registry (Urban et al., Eur Heart J, 2003, 24:604-612) and the only one to date showing efficacy of beta VBT in saphenous vein graft lesions.
41. Waksman R, Ajani AE, White RL, et al.: Intravascular gamma radiation for in-stent restenosis in saphenous-vein bypass grafts. N Engl J Med 2002, 346:1194-1199.
42. Sharma AK, Ajani AE, Garg N, et al.: Usefulness of gamma intracoronary radiation for totally occluded in-stent restenotic coronary narrowing. Am J Cardiol 2003, 91:595-597. This study examined retrospectively the subset of totally occluded restenotic lesions treated with gamma VBT and demonstrated its superior efficacy in comparison to placebo in this challenging patient subset with extremely high risk for restenosis recurrence.
43. Gruberg L, Waksman R, Ajani AE, et al.: The effect of intracoronary radiation for the treatment of recurrent in-stent restenosis in patients with diabetes mellitus. J Am Coll Cardiol 2002, 39:1930-1936. Demonstrates remarkable efficacy of VBT in significantly attenuating in-stent restenosis recurrence in comparison to placebo in patients with diabetes, a challenging patient subset with extremely high risk for repeat revascularization and other cardiovascular events following PCI.
44. Moses JW, Moussa I, Leon MB, et al.: Effect of catheter-based iridium-192 gamma brachytherapy on the added risk of restenosis from diabetes mellitus after intervention for in-stent restenosis (subanalysis of the GAMMA I Randomized Trial). Am J Cardiol 2002, 90:243-247. Demonstrates remarkable efficacy of VBT in significantly attenuating in-stent restenosis recurrence in comparison to placebo in patients with diabetes, a challenging patient subset with extremely high risk for repeat revascularization and other cardiovascular events following percutaneous coronary intervention.
45. Suntharalingam M, Laskey WK, Tantibhedhyangkul W, et al.: Vascular brachytherapy using a beta emitter source in diabetic patients with in-stent restenosis: angiographic and clinical outcomes. Int J Radiat Oncol Biol Phys 2003, 57:536-542. Demonstrates remarkable efficacy of VBT in significantly attenuating in-stent restenosis recurrence in comparison to placebo in patients with diabetes, a challenging patient subset with extremely high risk for repeat revascularization and other cardiovascular events following PCI.
46. Wolfram R, Cheneau E, Lew R, et al.: Effects of gamma radiation on the noninjured and unprotected left main. Catheter Cardiovasc Interv 2004, 61:477-481.
47. Waksman R, Lew R, Ajani AE, et al.: Repeat intracoronary radiation for recurrent in-stent restenosis in patients who failed intracoronary radiation. Circulation 2003, 108:654-656. This landmark study addressed an extremely important issue of safety and efficacy of repeat VBT in patients who failed the first VBT attempt for in-stent restenosis. Patients subjected to repeat VBT after first VBT failure had approximately half the incidence of MACE at 9 months in comparison to their counterparts referred to conventional revascularization.
48. Bass TA, Gilmore P, Zenni M, et al.: Debulking does not benefit patients undergoing intracoronary beta-radiation therapy for in-stent restenosis: insights from the START trial. Catheter Cardiovasc Interv 2003, 58:331-335.
49. Moses JW, Leon MB, Popma JJ, et al.: Sirolimus-elutiny stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003, 349:1315-1323. A first breakthrough pivotal study reporting the effects of sirolimus-eluting stent when compared to conventional bare metal stent of the same design. In 1086 patients randomized, a dramatic (-75%) reduction in TLR with the use with use of the sirolimus-eluting stent was observed. Multivariate analysis confirmed profound benefit regardless of baseline restenosis risk, which represents an unprecedented advantage over standard stents.
50. Holmes DR Jr, Leon MB, Moses JW, et al.: Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 2004, 109:634-640. This study provided evidence for sustained clinical benefit of sirolimus-eluting study out to 1 year of follow-up.
51. Schampaert E, Cohen EA, Schluter M, et al.: The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004, 43:1110-1115. A Canada-based sequel to the pivotal study by Holmes et al., Circulation 2004, 109:634-640, this study showed continued benefit of sirolimus-eluting stent despite more challenging small vessel diameter and longer lesion length.
52. Schofer J, Schluter M, Gershlick AH, et al.: Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003, 362:1093-1099. A European sequel to the pivotal study by Holmes et al. (Circulation 2004, 109:634-640), this study demonstrated sustained benefit of sirolimus-eluting stent despite more challenging small vessel diameter and longer lesion length.
53. Stone GW, Ellis SG, Cox DA, et al.: A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004, 350:221-231. A second seminal multicenter randomized study reporting the effects of paclitaxel-eluting stent when compared to conventional bare metal stent of the same design. In 1314 patients enrolled, a profound (-75%) reduction in TLR with the use with use of the paclitaxel-eluting stent was observed. Multivariate analysis confirmed profound benefit regardless of baseline restenosis risk, which represents an unprecedented advantage over standard stents.
54. Stone GW, Ellis SG, Cox DA, et al.: One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 2004, 109:1942-1947. This study provided evidence for sustained clinical benefit of paclitaxel-eluting study out to 1 year of follow-up.
55. Saia F, Lemos PA, Hoye A, et al.: Clinical outcomes for sirolimus-eluting stent implantation and vascular brachytherapy for the treatment of in-stent restenosis. Catheter Cardiovasc Interv 2004, 62:283-288. An early, single-center attempt at comparison of efficacy of sirolimus-eluting stent to VBT in the treatment of in-stent restenosis.
56. Bonan R: "At least but not at last" equivalent! Catheter Cardiovasc Interv 2004, 62:289. Superb editorial from a VBT expert providing a balanced perspective on the promise and premise of DES in the treatment of in-stent restenosis in comparison to VBT.
57. Waksman R: Vascular brachytherapy vs. drug-eluting stents for the treatment of in-stent restenosis: the jury's still out. Catheter Cardiovasc Interv 2004, 62:290-291. Another superb editorial from a VBT expert providing a balanced perspective on the promise and premise of DES in the treatment of in-stent restenosis in comparison to VBT.
58. Teirstein PS, King S: Vascular radiation in a drug-eluting stent world: it's not over till it's over. Circulation 2003, 108:384-385. Excellent commentary from eminent pioneers of VBT on the current relative position of DES and VBT in primary and secondary prevention of restenosis.
59. Waksman R, Weinberger J: Coronary brachytherapy in the drug-eluting stent era: don't bury it alive. Circulation 2003, 108:386-388. Another excellent commentary from eminent pioneers of VBT on the current relative position of DES and VBT in primary and secondary prevention of restenosis.